Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An extension study to assess the long-term safety and tolerability of OMS906 in patients with PNH

Next Previous
Trial Profile

An extension study to assess the long-term safety and tolerability of OMS906 in patients with PNH

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zaltenibart (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions

Most Recent Events

  • 13 Dec 2023 New trial record
  • 09 Nov 2023 According to an Omeros Corporation media release, Enrolled patients who have completed one of our two Phase 2 PNH studies evaluating OMS906 will move directly into the extension study without interruption of treatment. Data from this study will support a planned BLA for OMS906 in PNH.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top